Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Double-blind, Placebo-controlled, Randomized, Cross-over, Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-inhibitor Deficiency Type I and II

Next Previous
Trial Profile

A Phase II, Double-blind, Placebo-controlled, Randomized, Cross-over, Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-inhibitor Deficiency Type I and II

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deucrictibant (Primary) ; Icatibant
  • Indications Hereditary angioedema
  • Focus Proof of concept; Therapeutic Use
  • Acronyms RAPIDe-1
  • Sponsors Pharvaris

Most Recent Events

  • 02 Jun 2025 According to a Pharvaris media release, data from this trial were presented at the 14th C1-Inhibitor Deficiency and Angioedema Workshop.
  • 06 Mar 2024 According to a Pharvaris media release, efficacy and safety data from this trial will be presented at the 3rd ITACA National Congress, Milan, Italy, March 14-16, 2024 and HAEi Regional Conference Americas, Panama City, Panama, March 15-17, 2024.
  • 26 Jan 2024 According to a Pharvaris media release, result data from this trial will be presented at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting 2024, to be held from February 4-8, 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top